|Table of Contents|

Expression of ACKR1 in urothelial bladder cancer and its correlation with prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 20
Page:
3942-3947
Research Field:
Publishing date:

Info

Title:
Expression of ACKR1 in urothelial bladder cancer and its correlation with prognosis
Author(s):
LI Rupeng1; LUO Rong2; ZHAO Jian1; GAO Hongfei1
1.Department of Urology,the First Hospital of Shanxi Medical University,Shanxi Taiyuan 030001,China;2.Pathology Department,Wan Bailin Center Hospital,Shanxi Taiyuan 030024,China.
Keywords:
bladder cancer; ACKR1; chemokine; vascular invasion; tumor immune environment
PACS:
R737.14
DOI:
10.3969/j.issn.1672-4992.2024.20.023
Abstract:
Objective:To investigate the expression of atypical chemokine 1 (ACKR1) in urothelial bladder cancer (UBC) and its prognostic relevance.Methods:Transcriptome gene expression data from 428 UBC samples were collected for differential gene analysis and analysis of the tumor immune microenvironment using the ESTIMATE method.The clinical data of 81 bladder cancer patients admitted to the department of urology at our hospital from January 2019 to December 2021 were retrospectively analyzed.The patients were divided into a recurrence group (n=42) and a non-recurrence group (n=39) based on their prognosis.The study compared the clinical features between the two groups to identify any differences.Immunohistochemistry was used to detect ACKR1 expression in tissues and compare the differences in expression between intratumoral and peritumoral tissues in each layer of the bladder wall.The relationship between ACKR1 expression and clinicopathological characteristics of UBC patients was analyzed.The prognostic status of UBC patients was analyzed using the product-limit method (Kaplan Meier),and the significance of the comparisons was determined using the Log-Rank test.The Cox model was used to analyze the factors influencing poor prognosis in UBC patients.Results：Analysis of gene expression data from 428 samples showed that the expression of ACKR1 was reduced in tumor tissue and correlated with lower immune scores.The immunohistochemistry results of 81 patients with UBC combined with clinical data showed that the expression of ACKR1 in the peritumoral tissue of the lamina propria was higher in the non-recurrent group than in the recurrent group.Furthermore,individuals with tumor cells infiltrating the vasculature exhibited lower levels of ACKR1 expression compared to those without,and this difference was statistically significant.The group of patients with high expression of ACKR1 had a longer recurrence-free survival compared to the group with low expression of ACKR1 (P＜0.001).The results of the univariate Cox regression analysis indicated that patient recurrence was associated with differentiation grade,depth of infiltration,tumor size,choroidal infiltration,and ACKR1 expression.Multivariate Cox regression analysis that ACKR1 expression was an independent factor for bladder cancer recurrence (P＜0.05).Patients with high ACKR1 expression had a lower risk of recurrence compared to those with low ACKR1 expression (OR=0.032,95%CI:0.004 1~0.24,P＜0.05).Conclusion:Patients who have low expression of ACKR1 on the surface of capillary endothelial cells within the peritumoral tissue of the lamina propria may have a shorter recurrence-free survival.

References:

［1］ SIEGEL RL,GIAQUINTO AN,JEMAL A.Cancer statistics,2024［J］.CA Cancer J Clin,2024,74(1):12-49.
［2］ AGUS RIZAL AHH,FANNY RIANA R,DYANDRA P,et al.Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients［J］.BMC Urology,2020,20(1):158.
［3］ TULLIKA G,CARMIT KM,MICHAEL CL,et al.Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite,community-based cohort［J］.Cancer,2021,127(4):520-527.
［4］ TRAN L,XIAO JF,AGARWAL N,et al.Advances in bladder cancer biology and therapy［J］.Nature Reviews Cancer,2021,21(2):104-121.
［5］ THORSTEN RM,JULIA KL,LUKAS MA.How chemokines organize the tumour microenvironment［J］.Nature Reviews Cancer,2024,24(1):28-50.
［6］ SALUJA M,GILLING P.Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer:A review［J］.Int J Urol,2018,25(1):18-24.
［7］ PADMANEE S,SIWEN H,JENNIFER AW,et al.Primary,adaptive,and acquired resistance to cancer immunotherapy［J］.Cell,2017,168(4):707-723.
［8］ ROBERT JT,ELLIOTT JY,RICHARD DS,et al.Atypical chemokine receptors:emerging therapeutic targets in cancer［J］.Trends in Pharmacological Sciences,2022,43(12):1085-1097.
［9］ NAAMA R,AMOS JS,NINETTE A,et al.The Duffy antigen receptor for chemokines,ACKR1,-'Jeanne DARC' of benign neutropenia［J］.British Journal of Haematology,2019,184(4):497-507.
［10］ HUI SHEN,REBECCA SCHUSTER,KEITH F STRINGER,et al.The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth［J］.The FASEB Journal,2006,20(1):59-64.
［11］ WANG J,OU ZL,HOU YF,et al.Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential［J］.Oncogene,2006,25(54):7201-7211.
［12］ DANA H,JOZSEF B,MATTHEW E,et al.The role of the Duffy blood group antigens in renal transplantation and rejection.a mini review［J］.Transplant International,2023,36:11725.
［13］ LEE JS,FREVERT CW,WURFEL MM,et al.Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo［J］.The Journal of Immunology,2003,170(10):5244-5251.
［14］ HORUK R,MARTIN A,HESSELGESSER J,et al.The Duffy antigen receptor for chemokines:structural analysis and expression in the brain.［J］.Journal of Leukocyte Biology,1996,59(1):29-38.
［15］ MARTYNA S,GIULIA D,RAFAEL L,et al.New pairings and deorphanization among the atypical chemokine receptor family-physiological and clinical relevance.［J］.Frontiers in Immunology,2023,14:1133394.
［16］ ELIN S,MAX M,LAURA M,et al.A Novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer［J］.Clinical Cancer Research,2019,25(12):3702-3717.
［17］ YATES TJ,KNAPP J,GOSALBEZ M,et al.C-X-C chemokine receptor 7:a functionally associated molecular marker for bladder cancer［J］.Chinese Neuroregeneration Research (English version),2023,18(9):1976-1982.
［18］ SHAMS R,SEIFI-ALAN M,BANDEHPOUR M,et al.C-X-C chemokine receptor type 7 (CXCR-7) expression in invasive ductal carcinoma of breast in association with clinicopathological features［J］.Pathology Oncology Research,2020,26(2):1015-1020.
［19］ WAN W,LIU Q,LIONAKIS MS,et al.Atypical chemokine receptor 1 deficiency reduces atherogenesis in ApoE-knockout mice［J］.Cardiovascular Research,2015(3):478-487.
［20］ QUEENIE F,VARGHESE PHILIPOSE I,TAKWA B,et al.Chronic inflammation and cancer; the two sides of a coin［J］.Life Sciences,2023,338:122390.
［21］ MANTOVANI,ALBERTO,BONAVITA,et al.Atypical chemokine receptors in cancer:friends or foes［J］.Journal of Leukocyte Biology,2016,99(6):927-933.
［22］ SUCHARITA BANDYOPADHYAY,RUI ZHAN,ASOK CHAUDH URI,et al.Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression［J］.Nature Medicine,2006,12(8):933-938.
［23］ DIMITRA PA,AGATHE Q,CAMILLE LD,et al.An emerging paradigm of CXCL12 involvement in the metastatic cascade［J］.Cytokine & Growth Factor Reviews,2024,75:12-30.
［24］ TUO Z,FENG D,JIANG Z,et al.Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer:Insights from multiple omics analysis［J］.Chinese Journal of Cancer Research,2023,35(06):686-707.
［25］ MOHAMED A GHONEIM,MOHAMED ABDEL-LATIF,MOHSEN EL-MEKRESH,et al.Radical cystectomy for carcinoma of the bladder:2,720 consecutive cases 5 years later［J］.The Journal of Urology,2008,180(1):121-127.
［26］ KITAMURA H,TSUKAMOTO T,SHIBATA T,et al.Randomised phase III study of neoadjuvant chemotherapy with methotrexate,doxorubicin,vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer:Japan Clinical Oncology Group Study JCOG0209［J］.Annals of Oncology,2014,25(6):1192-1198.

Memo

Memo:
2023年度太原市“六个一批”科研项目(重点项目)(编号：Z2023005)
Last Update: 1900-01-01